To our knowledge, this is the largest study to investigate the hypothesis that TP53 Arg72Pro and MDM2 309T>G influence breast cancer risk in BRCA1 and BRCA2 mutation carriers individually or in combination. Here, TP53 is linked to breast carcinoma.